This was a quiet index week with a loud argument underneath it. From the August 7 close through Friday, August 14, the S&P 500 gained 0.36% to 7,785.76 and the Nasdaq Composite added 0.14% to 26,729.16. The Dow fell 0.56% to 53,732.41, while the Russell 2000 gained 1.12% to 3,068.42. The headline indexes barely moved. The internal rotation did not.
Oil took the lead. USO rose 7.31% and energy ETF XLE gained 7.67%, easily beating every other major sector group in our weekly screen. Small caps held up, software rose 1.35%, semiconductors gained 1.32%, and long-duration Treasuries lost 0.87%. That is not the rate-cut rally investors had a week earlier. It is a market willing to own cyclicality, cash flow, and smaller companies while asking more questions about the consumer.
The economic data supplied the tension. July CPI rose 0.1% from June and 3.4% from a year earlier, while core CPI rose 0.2% and 2.5%. Producer prices were unchanged on the month but remained 4.7% higher from a year earlier. Retail sales then fell 0.6% from June, even though they were still 5.0% above July 2025. Inflation did not break the tape. The consumer report did not break it either. But together they made the next rate decision and the next earnings guide less comfortable.
That leaves us with a market that is broad enough to study but not broad enough to trust blindly. Energy strength can help companies with real production and debt reduction. It does not rescue every cyclical. A large analyst target gap can create a useful entry. It does not excuse weak margins or bad guidance. The job this week is to separate businesses whose results held up from stocks whose upside still depends on a cleaner macro story than the data gave us.
The first one-week scorecard for Edition #28 is mixed in exactly the useful way. Fair Isaac gained 5.46%, Devon Energy rose 4.73%, BioCryst added 4.39%, and Crescent Energy gained 3.48%. AppLovin fell 9.10%, while Applied Digital rose 6.52% despite our NO TRADE verdict. A one-week move is not a completed thesis. It does show why verdicts need context. APP’s BUY got hurt immediately. APLD’s rally did not erase the financing and cash-burn risks that kept us out.
Key themes
Energy led by a wide margin, but the rest of the market did not behave like a simple inflation trade.
Small caps outperformed the large-cap indexes, giving the week more breadth than the flat S&P 500 close suggests.
Retail sales weakened while producer inflation stayed firm, leaving both consumer demand and margins under review.
The best setups combine a real target gap with reported cash flow or guidance. The weakest ask the target gap to do all the work.
2. Strengths
Small caps held while the large indexes stalled. Russell 2000 gained 1.12% and IWM rose 1.17%, ahead of the S&P 500, Nasdaq, and Dow. That matters because the prior rally was built around rate relief and large-cap technology. This week showed investors were still willing to move down the market-cap ladder even as Treasuries weakened. Software, semiconductors, health care, financials, industrials, utilities, and staples also finished positive. The caveat is that this was participation, not a breakout. Russell’s gain was useful, but it was nowhere near energy’s move and did not erase the financing pressure that still sits on weaker small companies.
Energy strength was supported by businesses that are already producing cash. XLE rose 7.67% and USO gained 7.31%. EQT fit that tape better than a speculative exploration story: it added 5.28% for the week after reporting 634 Bcfe of sales volume, $1.048 billion of operating cash flow, $330 million of attributable free cash flow, and a lower debt load. Management also raised full-year production guidance. The caution is valuation and timing. A stronger commodity week can improve sentiment quickly, but gas and oil prices remain volatile enough to reverse the same trade just as fast.
The prior edition’s patient calls generally worked. Fair Isaac’s BUY ON WEAKNESS gained 5.46%, Devon’s HOLD rose 4.73%, BioCryst’s SPECULATIVE BUY gained 4.39%, and Crescent’s HOLD rose 3.48%. That does not prove the selections are finished winners. It does show that waiting for valuation and operating evidence can still work in a market obsessed with immediate direction. AppLovin’s 9.10% loss is the counterweight. The company case may survive, but the entry did not. We record both, because a process that only remembers the good calls is not a process.
3. Weaknesses
The consumer blinked before the market did. July retail sales fell 0.6% from June. Consumer discretionary ETF XLY lost 1.39%, the weakest major sector in our screen, while staples gained 1.14%. That split does not prove a recession or a broad spending collapse. Retail sales were still 5.0% higher than a year earlier. It does warn that consumers may be shifting toward essentials and becoming less tolerant of price increases. For the next earnings cycle, revenue growth without traffic, units, or clean guidance will deserve more skepticism.
Inflation relief was incomplete. CPI’s 0.1% monthly increase was manageable and core CPI rose 0.2%, but producer prices were still 4.7% higher than a year earlier. TLT fell 0.87%, which is not what a clean rate-relief week looks like. The market can live with sticky producer inflation when nominal growth is strong. It becomes harder when retail demand is softening at the same time. Companies with weak pricing power or heavy input exposure now have less room for an execution miss.
Large target gaps still need operating proof. YETI, BROS, and FLNC all trade below analyst mean targets by meaningful amounts. Only one is a speculative buy. BROS has excellent revenue and comparable-shop growth, but its valuation remains demanding and the stock is below both moving averages. FLNC has a record backlog and real data-center awards, but margins collapsed and guidance was cut. The screen finds disagreement. It does not tell us which side is right. Earnings, cash generation, and balance-sheet resilience still decide whether the gap is opportunity or warning.
4. Weekly Market Recap
The week looked calm only from the index level. Energy took control, small caps kept participating, and most sectors finished positive, but the consumer and the bond market refused to confirm an easy soft-landing story. That is a workable environment for stock selection. It is a poor environment for buying labels. Cash flow mattered in energy, guidance mattered in cyclicals, and weak margin structures remained weak even when consensus targets looked generous. The market broadened just enough to create choices, not enough to remove discipline.
Thesis: CRH is a profitable infrastructure supplier going through a valuation reset, not a business waiting for a rescue. Second-quarter revenue reached $10.8 billion, up 6% from a year earlier. Net income rose 13% to $1.5 billion, adjusted EBITDA increased 7% to $2.6 billion, and diluted EPS rose 14% to $2.21. Adjusted EBITDA margin reached 24.4%. The stock still fell 3.31% for the week and is down 23.17% this year.
That split is the opportunity. The company reaffirmed full-year net income guidance of $3.9 billion to $4.1 billion, adjusted EBITDA of $8.1 billion to $8.5 billion, and diluted EPS of $5.60 to $6.05. Those are not turnaround promises. They are current-year operating expectations from a business that just grew revenue, profit, EBITDA, margin, and EPS.
Why now: CRH closed at $97.15, below both its $103.77 50-day average and $113.01 200-day average. The $136.32 mean target implies a 40.3% gap. More important, the published low target of $120 is still above Friday’s close. We do not treat that as guaranteed upside. It does tell us that the price reset has moved faster than the analyst earnings framework.
The acquisition strategy adds both upside and risk. CRH agreed to acquire Arcosa in an $8.5 billion transaction and had already invested about $1.4 billion across 17 acquisitions this year. The strategic logic is clear: add scale and deepen exposure to infrastructure demand. The burden is also clear: integration, leverage, capital allocation, and execution all become more important. A good operating quarter does not make every acquisition price correct.
The long-term case rests on assets and demand that are harder to replace than a consumer product cycle. Aggregates, cement, building products, and infrastructure exposure can benefit from public investment and local supply constraints. That does not make CRH immune to construction cycles. It does give management more levers than a company dependent on one product launch or one customer budget.
Model check: The one-day model is effectively neutral, forecasting $97.15 for August 17, a 0.002% gain at 50.05% confidence. The three-day model forecasts UP 0.02% to $97.17 for August 19 at 52.74% confidence. The seven-day model is more constructive, forecasting UP 1.18% to $98.30 for August 25 at 79.82% confidence. We agree with the seven-day direction, but not because a 1.18% forecast changes the thesis. It supports staged entry while the earnings and target-gap work do the real work.
The model’s 47.63% seven-day directional accuracy is not strong enough to follow blindly, even though its seven-day price accuracy is 95.12%. That difference is useful. It may estimate magnitude reasonably while still struggling to call direction. We use the output as a timing clue, not a substitute for judgment.
Risk and verdict: Construction demand, interest rates, acquisition integration, debt, input costs, and a prolonged move below the major averages are the main risks. BUY: accumulate in stages around the current reset. The $103.77 50-day average is the first recovery reference, followed by $113.01. The $136.32 mean target is a valuation reference if guidance and integration hold, not a promised return.
Thesis: Microchip is recovering from a painful semiconductor inventory cycle, and the latest quarter showed the recovery is real. Fiscal first-quarter net sales reached $1.485 billion, up 38% from a year earlier and 13.2% sequentially. GAAP gross margin was 63.2%, GAAP operating income was $336.8 million, and GAAP EPS was $0.37. On a non-GAAP basis, operating income reached $521.1 million, operating margin was 35.1%, and EPS was $0.76.
Cash conversion also improved. Operating cash flow was $511.5 million, capital spending was only $13.9 million, and free cash flow reached $497.6 million. The company returned $246.9 million through dividends. That is the kind of evidence needed before calling a cyclical recovery investable. Revenue growth alone can come from easy comparisons. Revenue, margin, and cash flow moving together are harder to dismiss.
Why on weakness: Management guided September-quarter sales to $1.589 billion to $1.618 billion, representing 7% to 9% sequential growth and about 40.6% year-over-year growth at the midpoint. Non-GAAP gross margin guidance is 66% to 67%, with operating margin of 38.5% to 39.5%. If delivered, those numbers would extend the recovery rather than merely repeat one good quarter.
The market is not giving Microchip full credit yet. Shares fell 6.52% for the week and closed at $79.17, below the $85.73 50-day average but still above the $76.14 200-day average. The $110.50 mean target sits 39.6% above the close. The setup is better than a stock that remains above both trend lines after a good quarter, but it is not a clean washout. Buyers are still paying for a recovery that must continue.
The 50.5x FY2026 consensus P/E is the reason this is BUY ON WEAKNESS rather than a plain BUY. Semiconductor earnings can look unusually expensive near a trough because the denominator is depressed. That can normalize quickly if sales and margins keep recovering. It can also stay expensive if customer inventories rise again or demand stalls. We want the operating rebound, but we do not need to chase every bounce.
Model check: The one-day model forecasts UP 0.42% to $79.51 for August 17 at 57.69% confidence. The three-day model forecasts UP 0.51% to $79.57 for August 19 at 67.24% confidence. The seven-day model forecasts UP 5.21% to $83.30 for August 25 at 88.97% confidence. We agree with the seven-day direction and use it as supporting evidence that the post-results weakness may stabilize. The one-day and three-day confidence readings are below 70%, so they do not justify an aggressive entry.
The model’s seven-day price accuracy is 93.37%, while directional accuracy is 51.68%. Again, the direction record is close to a coin flip. The high-confidence seven-day call helps with timing, but the BUY ON WEAKNESS verdict comes from the sequential sales acceleration, margin guidance, and free-cash-flow recovery.
Risk and verdict: Inventory correction, customer concentration, cyclical demand, manufacturing costs, debt, and a failed margin recovery are the main risks. BUY ON WEAKNESS: accumulate near the current range or on controlled pullbacks rather than chasing a fast rebound. The $76.14 200-day average is the key support reference. The $85.73 50-day average is the first recovery test. The $110.50 mean target requires the operating recovery to keep compounding.
Thesis: EQT had the right company results in the right sector week. Shares gained 5.28% as energy led the market. Second-quarter sales volume was 634 Bcfe, above the high end of guidance. Capital spending was $666 million, 9% below the low end of guidance, and operating costs were $1.03 per Mcfe. Operating cash flow reached $1.048 billion, and attributable free cash flow was $330 million.
The balance sheet is also moving in the right direction. Total debt fell to $5.7 billion and net debt to $5.5 billion, from $7.8 billion and $7.7 billion at the end of 2025. Liquidity was $3.6 billion. Management raised full-year production guidance by roughly 90 Bcfe to a range of 2,375 to 2,450 Bcfe and reduced maintenance capital guidance by $25 million.
Those facts support the business. They do not automatically support a fresh purchase after a strong commodity week. EQT closed at $54.42, above its $51.97 50-day average and below its $56.33 200-day average. The $72.50 mean target implies 33.2% upside, but the stock is already moving with a stronger gas and energy tape. The easy contrarian entry is gone for now.
Why hold: EQT’s commercial agreements improve the long-term case. The company signed a premium 10-year natural-gas supply agreement for 325,000 Dth per day and a five-year LNG offtake agreement for 0.5 million tonnes per year beginning in 2028. Management expects the LNG agreement to add about $45 million of annual free cash flow in 2028 at current strip prices. These contracts can improve market access and reduce dependence on a single local price point.
The other side is commodity exposure. Better production, lower debt, and disciplined capital spending matter, but natural-gas prices can still overpower execution in the share price. The stock’s 5.28% weekly gain and the energy sector’s 7.67% jump improve the chart while reducing the urgency to buy. HOLD respects both the company improvement and the less attractive entry.
Model check: The one-day model forecasts UP 0.04% to $54.44 for August 17 at 64.59% confidence. The three-day model forecasts UP 0.07% to $54.46 for August 19 at 67.70% confidence. The seven-day model forecasts UP 1.79% to $55.39 for August 25 at 72.32% confidence. We agree that the near-term bias can remain positive. We disagree that three small UP labels justify a BUY after the sector’s surge.
The seven-day directional accuracy is 54.91% and price accuracy is 94.59%. The output is constructive but not decisive. A forecast to $55.39 would still leave the stock below the $56.33 200-day average. That makes the model consistent with our HOLD: modest upside is possible, but the next technical and commodity test is close.
Risk and verdict: Natural-gas prices, basis differentials, production execution, leverage, regulatory exposure, and capital discipline remain the main risks. HOLD: retain a measured position if already owned, but do not chase the energy spike. The $51.97 50-day average is the nearest support reference. The $56.33 200-day average is the first major recovery test. The $72.50 mean target is reachable only if operating gains and the commodity backdrop persist.
6. Low-Cap Opportunities
The low-cap list keeps the same $2 billion to $15 billion market-cap ceiling and the same price-versus-consensus discipline.
Thesis: YETI’s 14.64% weekly decline created a more useful entry than the quarter deserved. Second-quarter sales rose 9% to $483.9 million. Coolers and equipment sales increased 16%, international sales rose 19%, GAAP EPS increased 54% to $0.94, and adjusted EPS rose 2% to $0.67. The company generated $48.1 million of free cash flow.
Margins require careful reading. GAAP gross margin expanded 890 basis points, including a 780-basis-point net tariff benefit. Adjusted gross margin increased 170 basis points, including a 60-basis-point tariff benefit. The improvement is real, but part of the headline move came from a benefit that should not be treated as permanent operating leverage. That is one reason the verdict stays speculative.
Management maintained sales-growth guidance of 7% to 8%, raised adjusted operating-margin guidance to about 14.9% from 14.6%, and raised adjusted EPS guidance to $2.94-$3.00 from $2.83-$2.89. It also repurchased about $130 million of stock, or 2.8 million shares. Those actions support the view that the selloff reset expectations more than it invalidated the business.
Verdict: SPECULATIVE BUY: the $44.54 close is just above the $43.87 200-day average and below the $49.68 50-day average. The $56.25 mean target implies 26.3% upside, enough to justify a small position but not enough to ignore consumer sensitivity, tariffs, brand competition, and the sharp price reaction. Keep sizing modest. A sustained break below the 200-day average weakens the setup; reclaiming $49.68 would be the first recovery signal.
Thesis: Dutch Bros is growing too quickly to dismiss and trades too richly to chase. Second-quarter revenue rose 32.5% to $550.9 million. The company opened 48 shops, including 44 company-operated locations. Company-operated same-shop sales increased 8.3%, with transactions up 3.4%. Systemwide same-shop sales rose 5.8%, with transactions up 1.7%.
Profit growth kept pace. Net income rose to $51.6 million from $38.4 million, while adjusted EBITDA increased 27.8% to $113.7 million. Management guided full-year revenue to $2.10-$2.13 billion, systemwide same-shop sales growth to 5%-6%, and adjusted EBITDA to $385-$390 million. It expects at least 185 openings and capital spending of $350-$370 million.
That combination is impressive. It is also expensive. BROS closed at $52.02, below both its $63.66 50-day average and $57.65 200-day average, yet still trades at 54.8x FY2026 consensus EPS. The $77.82 mean target gives a 49.6% gap, but the market is asking whether unit growth, transaction growth, and margins can keep compounding while the company spends heavily on expansion.
Verdict: HOLD: existing holders can wait for the growth story to mature, but new buyers do not need to catch the stock below both trend lines at this valuation. Reclaiming the $57.65 200-day average would improve the setup. A move toward the $63.66 50-day average would show that the market is beginning to trust the guide. Until then, good results and a demanding multiple cancel each other out.
3. Fluence Energy (FLNC) – NO TRADE
$13.14 | $2.42B market cap | No positive forward P/E | 50-day / 200-day: $17.47 / $18.69 | Mean target: $18.45 | Target gap: +40.4%
Thesis: Fluence has demand and backlog. It does not yet have the execution or margins required for fresh capital. Fiscal third-quarter revenue reached $649.8 million, up from $602.5 million a year earlier, but production delays left the result below expectations. GAAP gross margin fell to 5.1% from 14.8%, adjusted gross margin fell to 5.9% from 15.4%, and net loss reached $44.3 million. Adjusted EBITDA was negative $29.3 million.
The bull case is easy to see. Quarterly order intake was $1.44 billion, nearly triple the prior-year period, and backlog reached a record $6.4 billion. Through July, Fluence had secured about $850 million of data-center business, including roughly $550 million of awards from hyperscale customers. Liquidity was $863 million, including $365 million of cash.
The problem is conversion. Management cut full-year revenue guidance to $2.9-$3.1 billion from $3.2-$3.6 billion and reduced adjusted EBITDA guidance to a range of negative $30 million to positive $10 million from positive $40-$60 million. A large backlog is only valuable if projects can be delivered at acceptable margins. This quarter did not prove that.
Verdict: NO TRADE: the $18.45 mean target is 40.4% above the close, but the company has no positive forward P/E, sits below both major moving averages, and just cut both revenue and EBITDA guidance. Wait for evidence that delays are easing and margins are recovering. The backlog can keep FLNC on the watchlist. It cannot compensate for weak conversion today.
7. Strategic Recap & Forward Outlook
Energy surged, small caps held, and most sectors stayed positive, while the Dow slipped and consumer discretionary weakened. The macro data left both sides of the soft-landing argument alive: CPI was manageable, producer inflation remained firm, and retail sales fell. That is enough uncertainty to keep stock selection more useful than a blanket sector call.
Our response is straightforward. Buy CRH because the valuation reset is backed by current profit growth and reaffirmed guidance. Buy Microchip on weakness because the semiconductor recovery is visible in sales, margins, and free cash flow, but the valuation still demands a patient entry. Hold EQT because operating performance and debt reduction are strong, yet the energy rally already pulled the stock toward its next technical test. In low caps, YETI earns speculative sizing. Dutch Bros remains a HOLD. Fluence stays a NO TRADE until backlog converts into margin.
Forward Outlook
Monday, August 17 – Empire State Manufacturing and the New York Fed’s consumer labor-market survey open the week. Watch whether manufacturing and job expectations support the small-cap bid.
Tuesday, August 18 – Import and export prices, housing starts and permits, industrial production, and pending home sales arrive. Home Depot reports, giving the market a direct read on housing-linked demand and the consumer.
Wednesday, August 19 – Minutes from the July 28-29 FOMC meeting are the main macro checkpoint. Target, Lowe’s, TJX, and Analog Devices report. The mix will test consumers, housing, and semiconductors in one session.
Thursday, August 20 – Initial jobless claims and the Philadelphia Fed survey arrive. Walmart, Deere, Alibaba, and Ross Stores report, making this the week’s clearest test of consumer resilience and industrial demand.
Friday, August 21 – State employment and unemployment data close the calendar. The practical check is breadth: can small caps and non-energy sectors keep participating after a week led by commodities?
Disclaimer: StockResearch Intelligence Weekly is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All data is sourced from third-party providers and believed accurate as of the publication date but is not guaranteed. Price targets and verdicts reflect the author’s analysis and may change without notice. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Conduct your own research and consult a licensed financial advisor before making investment decisions. The author may hold positions in securities mentioned.
Oil, Inflation and the Fed Keep the Pressure on Stocks | Week Ending Sep 11, 2026
Cookies on StockResearch
We use essential cookies to run this site. With your OK we also use analytics cookies (Google Analytics) to see which pages help investors. You can change your choice any time from Cookie settings in the footer.
Choose what we may store in your browser. Essential cookies stay on because the site needs them.
